Gene therapy holds promise for chronic lymphocytic leukemia

08/10/2011 | Wall Street Journal, The · Reuters

Scientists at the University of Pennsylvania destroyed tumors in three patients with chronic lymphocytic leukemia less than a month after administering the patients' T-cells that were genetically engineered to stimulate the immune system to hone in on the CD19 protein, which is found on blood cancer cells. Two patients achieved complete response to the treatment, while the third exhibited partial response. The therapy needs to be tested in more patients to validate the findings, the study's principal investigator said.

View Full Article in:

Wall Street Journal, The · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations